📷 Image: Wikimedia Commons / Anika sharma
Health
Crowdfunding Raises Over ₹9 Crore for Indore Child Anika Sharma’s SMA Type‑2 Treatment
✍️ Amar Ujala · Indore
🗓 19 Oct 2026, 08:00 AM
👁 17
A crowdfunding campaign has collected more than ₹9 crore to fund treatment for Anika Sharma, a child from Indore diagnosed with spinal muscular atrophy type‑2.
Indore resident Anika Sharma, a young patient suffering from spinal muscular atrophy (SMA) type‑2, has secured the financial resources needed for her therapy. SMA type‑2 is a rare genetic disorder that progressively weakens muscles and can limit mobility.
A crowd‑sourced fundraising drive organized by local supporters amassed more than ₹9 crore, surpassing the estimated cost of the specialized treatment regimen. The campaign attracted contributions from individuals across the country, reflecting widespread public empathy for the child's condition.
With the funds now available, the medical team overseeing Anika’s care is preparing to initiate the prescribed treatment protocol. Hospital officials confirmed that the therapy can commence without further delay, pending standard medical clearances.
The successful fundraising effort underscores the growing role of community‑driven financing in addressing high‑cost medical needs in India, especially for rare diseases that lack extensive insurance coverage.
A crowd‑sourced fundraising drive organized by local supporters amassed more than ₹9 crore, surpassing the estimated cost of the specialized treatment regimen. The campaign attracted contributions from individuals across the country, reflecting widespread public empathy for the child's condition.
With the funds now available, the medical team overseeing Anika’s care is preparing to initiate the prescribed treatment protocol. Hospital officials confirmed that the therapy can commence without further delay, pending standard medical clearances.
The successful fundraising effort underscores the growing role of community‑driven financing in addressing high‑cost medical needs in India, especially for rare diseases that lack extensive insurance coverage.